
1. j nat prod. 2014 mar 28;77(3):483-8. doi: 10.1021/np400701k. epub 2014 jan 27.

nf-κb inhibitors eurycoma longifolia.

tran tv(1), malainer c, schwaiger s, atanasov ag, heiss eh, dirsch vm, stuppner
h.

author information: 
(1)institute pharmacy/pharmacognosy, center molecular biosciences
innsbruck, university innsbruck , austria.

the roots eurycoma longifolia used many countries southeast
asia alleviate various diseases including malaria, dysentery, sexual
insufficiency, rheumatism. although numerous studies reported the
pharmacological properties e. longifolia, mode action the
anti-inflammatory activity elucidated. bioguided isolation nf-κb 
inhibitors using nf-κb-driven luciferase reporter gene assay led the
identification new quassinoid, eurycomalide c (1), together 27 known
compounds including 11 quassinoids (2-12), six alkaloids (13-18), two coumarins
(19, 20), squalene derivative (21), triterpenoid (22), six phenolic
compounds (23-28) extract e. longifolia. evaluation biological
activity revealed c19-type c20-type quassinoids, β-carboline, and
canthin-6-one alkaloids potent nf-κb inhibitors, ic50 values low 
micromolar range, c18-type quassinoids, phenolic compounds, coumarins, 
squalene derivative, triterpenoid turned inactive tested
at concentration 30 μm. eurycomalactone (2), 14,15β-dihydroklaieanone (7),
and 13,21-dehydroeurycomanone (10) identified potent nf-κb inhibitors
with ic50 values less 1 μm.

doi: 10.1021/np400701k 
pmcid: pmc3971761
pmid: 24467387  [indexed medline]

